CD274 and myocarditis: A novel radiotracer targeting PD-L1 has been developed that may allow the quantification of myocardial PD-L1 expression,8 though this requires further investigation in prospective clinical trials to determine its role in predicting risk for developing myocarditis from ICI therapy.